| Aug 26 |
TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology
|
| Aug 13 |
Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts
|
| Aug 12 |
TScan Therapeutics GAAP EPS of -$0.28, revenue of $0.5M
|
| Aug 12 |
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates
|
| Aug 12 |
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Jun 24 |
TScan Therapeutics Decline Means Insider Profits Down To US$54k
|
| Jun 24 |
Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 11.6% Jump Turn into More Strength?
|
| Jun 14 |
TScan Therapeutics Announces Updates to its Board of Directors
|
| May 30 |
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
|
| May 29 |
TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
|
